Paridiprubart (NI-0101) is a humanised monoclonal antibody targeting TLR4, demonstrating ameliorative effects in COVID-19 patients with acute respiratory distress syndrome (ARDS) and holding potential for rheumatoid arthritis research.
Purity:
0.985
CAS Number:
[2641646-59-3]
Target:
TLR
* VAT and and shipping costs not included. Errors and price changes excepted